NCT03210649已完成1 期
A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers : Part I- Single Dosing / Part II- Multiple Dosing
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Maximum Plasma Concentration [Cmax] of CKD-519
研究概览
简要总结
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519
详细描述
A randomized, double-blind, placebo-controlled, phase I clinical trial to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519 after oral administration in healthy adult volunteers Part I- single dosing / Part II- multiple dosing
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Between 19 aged and 55 aged in healthy adult
- •Body weight more than 55kg in male, 50kg in female
- •Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)
- •If female, must include more than one among the items
- •The menopause(there is no natural menses for at least 2 years)
- •Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition
- •If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms and do not sperm donation until two months during clinical trials and after the final dosage of investigational products
- •Those who fully understand about this clinical trials after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent
排除标准
- •Have clinically significant disease that hepatobiliary system(severe hepatic impairment, etc), kidney(severe renal impairment, etc), nervous system, immune system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular system(heart failure, etc) or mental illness, or a history of mental disease.
- •Have a history of Toresades de pointes(TdP) or additional risk factors for Toresades de pointes(TdP). (Family history of long QT syndrome or sudden death, heart failure, hypokalemia, etc)
- •Have a gastrointestinal disease history that can effect drug absorption(Crohn's disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)
- •Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives.
- •An impossible one who participates in clinical trial including screening tests(medical history taking, BP, 12-lead ECG, physical examination, blood&urine laboratory test result) before 28 days the taking investigational Products.
- •Defined by the following laboratory parameters
- •AST, ALT>1.25 upper limit of normal range
- •Total bilirubin>1.5 upper limit of normal range
- •CPK>1.5 upper limit of normal range
- •eGFR(using by MDRD method)<60mL/min/1.73m2
- •Defined by the following 12-lead ECG
- •HR<40 or >110bpm
- •PR interval>220ms or ≤110ms
- •QRS interval>120ms
- •QTcF<300ms or >450ms
- •Pathologic Q-waves (defined as >40ms or depth>0.5mV)
- •Incomplete or complete bundle branch block
- •Pre-excitation (e.g., Wolfe-Parkinson-White Syndrome)
- •Atrial fibrillation/flutter
- •Second- or third-degree atrioventricular (AV)block
- •Investigator judges to be unfavorable for consistently accurate QT measurements(e.g., indistinct QRS onset, low amplitude T wave, inverted or terminally inverted T wave, merged T/U waves, indistinct T wave offset , or prominent U wave that affects QT measurement)
- •Sitting SBP>150mmHg or <90mmHg, sitting DBP>100mmHg or <50mmHg, after 5 minutes break.
- •Drug abuse or have a history of drug abuse shows a positive for urine drug test.
- •Pregnant or lactating women.
- •A heavy caffeine consumer(caffeine>5 cups/day), alcohol consumer (alcohol>210g/week), or smoker(cigarette>10 cigarettes/day)
- •Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of subjects.
- •Subject who takes inhibitor and inducers of drug metabolizing enzyme (Barbiturates etc.) within 30 days.
- •Taking concomitant medications that prolong the QT/QTc interval within 14 days before the beginning of study treatment.
- •Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7days before the beginning of study treatment)
- •Subject who treated with any investigational drugs within 90 days before the beginning of study treatment
- •Previously donate whole blood within 60 days or component blood within 30 days.
- •An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
- •Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
研究组 & 干预措施
CKD-519 400mg(PartⅠ: 1day)
Experimental
CKD-519 400mg(100mg x 4tabs) or placebo
干预措施: CKD-519 (Drug)
CKD-519 400mg(PartⅠ: 1day)
Experimental
CKD-519 400mg(100mg x 4tabs) or placebo
干预措施: Placebo (Drug)
CKD-519 400mg(PartⅡ: 14days)
Experimental
CKD-519 400mg(100mg x 4tabs) or placebo
干预措施: CKD-519 (Drug)
CKD-519 400mg(PartⅡ: 14days)
Experimental
CKD-519 400mg(100mg x 4tabs) or placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Maximum Plasma Concentration [Cmax] of CKD-519
时间窗: Part I - Day1: 0(predose)~168hour, Part II - Day1: 0(predose)~24hour, Day3~Day13:0(predose), Day14: 0(predose)~168hour
Pharmacokinetics after administration of single and multiple doses
次要结局
- Pharmacodynamics(Lipid Parameter) of CKD-519(PartⅡ- Day1, Day3, Day7, Day10, Day12, Day14, Day15, Day16, Day17, Day21)
- Pharmacodynamics(QC/QTc) of CKD-519(Part II - Day-1, Day 1, Day14)
- Pharmacodynamics(CETP) of CKD-519(Day1: 0(predose)~168hour)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese ParticipantsHealthy VolunteerNCT04461483Takeda33
尚未招募
1 期
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesIgA NephropathyNCT06774664Sinocelltech Ltd.99
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671GoutHyperuricemiaNCT04060173Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.27
招募中
1 期
A Study of HS-10501 Tablets in Healthy SubjectsHealthy SubjectsNCT06359600Jiangsu Hansoh Pharmaceutical Co., Ltd.84
招募中
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult SubjectsHealthy Adult SubjectsNCT06635226IlDong Pharmaceutical Co Ltd36